TOP > 外国特許検索 > CARRIER FOR DRUG DELIVERY USE

CARRIER FOR DRUG DELIVERY USE NEW

外国特許コード F200010022
整理番号 (S2018-0655-N0)
掲載日 2020年1月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP017921
国際公開番号 WO 2019225296
国際出願日 平成31年4月26日(2019.4.26)
国際公開日 令和元年11月28日(2019.11.28)
優先権データ
  • 特願2018-099998 (2018.5.24) JP
発明の名称 (英語) CARRIER FOR DRUG DELIVERY USE NEW
発明の概要(英語) A carrier for drug delivery use, comprising a human serum albumin variant in which a mannose-rich sugar chain having 8 or more mannose residues is bonded to a substance capable of interacting with the mannose-rich sugar chain or a binding site in the substance capable of interacting with the mannose-rich sugar chain.
従来技術、競合技術の概要(英語) BACKGROUND ART
New refractory cancer as a therapeutic target, the characteristic of tumor tissue in the tumor microenvironment interstitial has attracted attention. This is because the growth of cancer the tumor microenvironment, transition, or progression in a cause of drug resistance.
Comprising a target molecule in a variety of anti-cancer drugs in recent years and although the significant progress in the treatment method, a single agent cannot kill the cancer. This is because, in the cancer microenvironment (TAM) and tumor-associated macrophage-associated fibroblasts (CAF) or the like to control the group of cells is yet to be established therapeutic strategy because it does not. M2 TAM is as macrophages, the occurrence of a malignant tumor from the initial to the formation of metastases of course, that is, the growth of cancer cells, invasion, metastasis and involved, treatment of malignant tumor microenvironment is positioned as a resistance factor.
Also, the CAF, proliferation, and excellent mobility, cancer cell proliferation, invasion, metastasis only play an important role in the course but, to promote overgrowth of the extracellular matrix, anti-tumor penetration of the treatment due to the attenuation of the calibration resistance occurs. Further, cancer stem cells and the signaling link and the CAF of cancer stem cells may be important to survival have been reported (for example, see Non-Patent Document 1.).
Interestingly, cancer microenvironment CAF TAM CD280 and high CD206 expression to cancer tissues there are a number of highly expressed, the higher the grade, is a poor prognosis and treatment-resistant depression from the clinical observations have been demonstrated.
However, human serum albumin (hereinafter, referred to as' HSA '.) Is a simple protein, sugar chain does not have. On the other hand, the inventors have found that, previously, the HSA N- coupling type sugar chain binding amino acid sequence to form a site-directed mutagenesis (D63N, A320T, D494N) is introduced, this can be produced in the yeast, yeast expression systems are specific to the HSA high-mannose sugar chain bound to (or less, 'Man-HSA' may be referred to.) Was successful for the first time to produce (for example, see Non-Patent Document 2.) Further, Man-HSA is prepared, the target CD280 and CD206 has the ability, healthy mice and fibrosis model by a mouse has been confirmed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • MARUYAMA Toru
  • WATANABE Hiroshi
  • ISHIMA Yu
  • MAEDA Hitoshi
  • MIZUTA Yuki
  • KINOSHITA Ryo
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close